Abstract: A pearlescent composition containing: (a) a dialkyl ether corresponding to formula (I): R1—O—R2??(I) wherein R1 and R2 independently of one another represent linear or branched alkyl and/or alkenyl groups having from 12 to 22 carbon atoms; (b) a cationic polymer; and (c) an emulsifier selected from the group consisting of a fatty acid-N-alkyl polyhydroxyalkyl amide, an alkyl ether sulfate, a betaine, and mixtures thereof.
Abstract: A method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A? peptides.
Type:
Grant
Filed:
May 17, 2001
Date of Patent:
April 12, 2005
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Robert Zaczek, Richard E. Olson, Dietmar A. Seiffert, Lorin A. Thompson
Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.
Type:
Grant
Filed:
February 5, 2003
Date of Patent:
April 5, 2005
Assignee:
Genzyme Corporation
Inventors:
W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
Abstract: The present invention is directed, in general, to contrast agents (CA), and methods and systems of using such agents for producing image contrast based on a magnetization transfer (MT) mechanism. The CA comprises a tetraazacyclododecane ligand having pendent arms R, R?, R? and R?? that are amides having a general formula: —CR1H—CO—NH—CH2—R2. R1 includes organic substituents and R2 is not hydrogen. A paramagnetic metal ion (M) is coordinated to the ligand. The method, comprises subjecting a CA, in a sample, to a radio frequency pulse. The CA has pendent arms R, R?, R? and R?? comprising organic substituents and the ligand further includes a M and a water molecule. A signal is obtained by applying a radio frequency pulse at a resonance frequency of the water molecule. The magnetic resonance system, comprises a magnetic resonance apparatus and the CA, the agent containing a ligand having the above described general formula.
Type:
Grant
Filed:
November 20, 2001
Date of Patent:
April 5, 2005
Assignee:
Board of Regents The University of Texas System
Inventors:
A. Dean Sherry, Shanrong Zhang, Kuangcong Wu
Abstract: The present invention provides a method for detecting chitin-containing organisms on an area of a person or animal by contacting the particular area with a dye that is capable of binding or conjugating to chitin and emitting fluorescence upon exposure to light. If a chitin-containing organism is present in the treated area, the chitin of the organism will bind or conjugate the dye and, upon exposure to light, the chitin-containing organisms may be visualized and removed. Also provided by the present invention are solutions and suspensions that contain a dye capable of binding or conjugating to a chitin-containing organism and emitting fluorescence upon exposure to light. The solutions and suspensions provided herein may be in the form of a shampoo, cream, lotion or detergent for the detection of chitin-containing organisms present in body hair, on the skin, clothing or the fur of animals.
Type:
Grant
Filed:
July 22, 2002
Date of Patent:
April 5, 2005
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
Edward R. Burns, Murray Wittner, Fagie Faskowitz
Abstract: This invention is directed to the use of radiopharmaceuticals in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.
Type:
Grant
Filed:
July 25, 2003
Date of Patent:
March 29, 2005
Assignee:
Schering AG
Inventors:
Christoph-Stephan Hilger, Bernd Johannsen, Joerg Steinbach, Peter Maeding, Meredith Halks-Miller, Richard Horuk, Harald Dinter, Raju Mohan, Joseph E. Hesselgesser
Abstract: The present invention is a thermally reversible stimulus-sensitive gel or gelling copolymer radioisotope carrier that is a linear random copolymer of an [meth-]acrylamide derivative and a hydrophilic comonomer, wherein the linear random copolymer is in the form of a plurality of linear chains having a plurality of molecular weights greater than or equal to a minimum gelling molecular weight cutoff. Addition of a biodegradable backbone and/or a therapeutic agent imparts further utility. The method of the present invention for making a thermally reversible stimulus-sensitive gelling copolymer radionuclcide carrier has the steps of: (a) mixing a stimulus-sensitive reversible gelling copolymer with an aqueous solvent as a stimulus-sensitive reversible gelling solution; and (b) mixing a radioisotope with said stimulus-sensitive reversible gelling solution as said radioisotope carrier.
Type:
Grant
Filed:
May 9, 2001
Date of Patent:
March 22, 2005
Assignee:
Battelle Memorial Institute
Inventors:
Richard E. Weller, Michael A. Lind, Darrell R. Fisher, Anna Gutowska, Allison A. Campbell
Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
Abstract: Compounds and methods for the diagnosis and treatment of tumors, including breast and prostate tumors and metastases thereof using radiolabelled peptides that bind to GRP receptors. The peptides are Bombesin analogs wherein the first and optionally the third amino acid are modified.
Type:
Grant
Filed:
February 6, 2003
Date of Patent:
March 15, 2005
Assignee:
Mallinckrodt Inc.
Inventors:
Jean-Claude Reubi, Wout A. Breeman, Ananthachari Srinivasan
Abstract: An object of the present invention is to provide pharmaceutical compositions for inhibiting mesangial cell proliferation or mesangial matrix production without causing hypercalcemia. According to the present invention, therapeutic agents for glomerulosclerosis containing 1?,3?-dihydroxy-20?-(3-hydroxy-3-methylbutyloxy)-9,10-seco-5,7,10 (19)-pregnatriene as an active ingredient are provided.
Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.
Type:
Grant
Filed:
December 11, 2002
Date of Patent:
February 15, 2005
Assignee:
Schering, AG
Inventors:
Johannes Platzek, Heribert Schmitt-Willich, Heinz Gries, Gabriele Schuhmann-Giampieri, Hubert Vogler, Hanns-Joachim Weinmann, Hans Bauer
Abstract: Tumors expressing VPAC receptors can be imaged or treated with compounds comprising PACAP, or a biologically active PACAP fragment or analog.
Abstract: The present invention relates to novel complexes of (transition) metals containing ligands having phosphorus centers supporting a carbene atom or heteroalkane radical bonded to the (transition) metal.
Type:
Grant
Filed:
February 3, 2003
Date of Patent:
February 8, 2005
Assignee:
The Governors of the University of Alberta
Inventors:
Ronald G. Cavell, Ruppa P. Kamalesh Babu, Aparna Kasani
Abstract: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug delivery devices for implantation prepared from the polymers of the present invention are also disclosed.
Type:
Grant
Filed:
November 5, 2002
Date of Patent:
February 8, 2005
Assignee:
Rutgers, The State University
Inventors:
Joachim B. Kohn, Durgadas Bolikal, Sanyog M. Pendharkar
Abstract: The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.
Type:
Grant
Filed:
July 12, 2002
Date of Patent:
January 25, 2005
Assignee:
The Regents of the University of California
Inventors:
Kenneth N. Raymond, Daniel M. J. Doble, Christopher J. Sunderland, Marlon Thompson
Abstract: The present invention provides methods and compositions for imaging cell death in vivo, as well as methods and compositions for tumor radiotherapy.
Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.
Abstract: Piperazine or piperidine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The piperazine or piperadine compounds are characterized by the formula:Formula I
wherein:
A is oxygen; n is an integer of 1 to 6; X and Y can be the same or different and are hydrogen, halogen, nitro, alkyl or halalkyl, Z is carbon or nitrogen; and &phgr; is phenyl, naphthyl, thienyl or pyridinyl.
When Z is carbon, R is hydrogen, cyano, hydroxy, —COOCH3, —CH20H or —COOH; R1 is 4-fluorophenyl, 4-chlorophenyl, 4-trifluoromethyl, 3-trifluoromethyl-4 -chlorophenyl 4-bromophenyl), 4-(2-keto-1-benzimidazolinyl or 1-phenyl 1, 3, 8-triazaspiro [4,5] decan-4-one.